Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
The participants are being asked to take part in this trial, because the participant is a survivor of childhood cancer or agreed to be part of a volunteer group to understand the relation between cancer and cancer treatment and muscle weakness in survivors of Acute Lymphoblastic Leukemia (ALL). ALL is cancer of the blood and bone marrow.
Primary Objective
• To compare muscle mtOXPHOS activity and satellite cell content among ALL survivors and controls.
Secondary Objective
- To evaluate the association between muscle mtOXPHOS, muscle satellite cell content and physical performance in ALL survivors.
- To evaluate the association of muscle morphology and epigenetics with muscle mtOXPHOS in ALL survivors.
Full description
This study hypothesizes that sarcopenia (low lean mass and muscle weakness), the central components of frailty, result from cancer- and or treatment-related impairment of cellular function within skeletal myocytes. Impaired mitochondrial oxidative phosphorylation (mtOXPHOS) is a hallmark of aging and implicated in skeletal muscle (muscle) weakness and lowered physical performance with normal aging. There is a lack of understanding of how the dysfunctional mitochondrial capacity affects the individual muscle groups in the lower extremities of the survivors.
This pilot study will explore the feasibility of non-invasive metabolic imaging to measure the major muscle groups in the calf muscle mtOXPHOS in childhood survivors of Acute Lymphoblastic Leukemia (ALL) in SJLIFE cohort by incorporating magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in survivors and age/sex-matched healthy volunteers (Controls). Control participants will be recruited from SJLIFE control cohort and may be recruited from new SJLIFE controls; The MRI/MRS findings will be correlated with clinically ascertained muscle phenotype; and will explore and describe differences in muscle morphology, epigenetics, mtDNA-CN between survivors and controls using peripheral blood and muscle biopsies, and their association with MRI/MRS findings.
Survivor and Control participants will be asked to have two MRI sessions; a physical function, and a muscle ultrasound assessment done during SJLIFE Human Performance Lab (HPL). Participants will be asked to give a peripheral blood sample and muscle sample. MR imaging will be performed in two appointments.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Survivor- or Control-Participant is age 18 years old or older at time of consent and enrolled in SJLIFE.
- Survivor- Participant is childhood ALL survivor
- Survivor- or Control Participant has low muscle mass as defined by relative lean mass z-score of less than or equal to -0.5 SD (lean mass divided by height in meters squared).
- Survivor- or Control-Participant is able and willing to give informed consent
Exclusion criteria
- Survivor-Participant has history of cranial radiation.
- Survivor- or Control-Participant has implanted medical devices or metal that would interfere with MRI or MRS
- Female Survivor- or Control-Participant is pregnant.
- Survivor- or Control-Participant is taking anticoagulants (e.g. aspirin, apixaban, coumadin, edoxaban, rivaroxaban)
- Survivor- or Control-Participant weighs more than 300 pounds.
- Survivor- or Control-Participant is allergic to local anesthetic (i.e., lidocaine, bupivacaine).
- Survivor- or Control-Participant cannot lie flat on his/her back for 90 minutes or longer
- Survivor- or Control-Participant has a current history of peripheral motor neuropathy.
Trial design
Primary purpose
Allocation
Interventional model
Masking
60 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Puneet Bagga, PhD; Puneet Bagga, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal